心血瘀阻

心血瘀阻证及痰浊壅塞证在重度狭窄中具有统计学意义（P均0.05），且在病变范围上均显著高于其他证型组（P均0.05）。

There were differences in heart blood stasis syndrome and phlegm-turbid retention syndrome in severity stenosis ( P0.05 ) and in branches lesion group ( P0.05 ) .

结论FⅦ基因M1M1多态性和M1等位基因与CHD心血瘀阻证相关；

Conclusion The polymorphism of F ⅶ gene and the allele M1 was associated with the HBSS of CHD ;

两个心血瘀阻证组3个基因型的Ag活性均明显高于健康人对照组（P<0.01）。

Ag ⅱ activity of three gene types in two groups of heart blood stasis syndrome was higher than that in healthy control group ( P < 0.01 ) .

结果CHD心血瘀阻证组DD基因型和D等位基因的频率显著高于其他3组；

Results The frequency of DD type and D allele in group of CHD with heart blood stasis syndrome was higher than those in other three groups .

CHD心血瘀阻证组ACE基因DD型亦较ID基因型患者的Ag活性显著增高（均P<0.01）。

Ag ⅱ activity of DD type was higher than that of ID type in group of CHD with heart blood stasis syndrome [ WTBX ] ( P < 0.05 ) .

冠心病组外周ghrelin水平心血瘀阻、气虚血瘀组显著小于健康对照组（p0.05），辨证分型之间无统计学差异。

The CHD group ghrelin levels with blood stasis due to friction , and blood stasis are much smaller than group health in control group ( p0.05 ), dialectical points between type not statistically different .

该药在临床用药过程中无发生不良反应，说明其安全可靠可为防治心血瘀阻型冠心病患者PCI术后引发的心肌缺血再灌注损伤的临床用药提供参考。

The drug in the clinical course of medication adverse reactions , its safe and reliable and can provide a reference for clinical drug prevention efforts stasis type in patients with coronary heart disease after PCI-induced myocardial ischemia and reperfusion injury .

心血瘀阻与痰阻心脉两型GSH含量及GSH／GSSG比值较其他两型降低（P<0.05），向氧化方向偏移。

GSH content and the GSH / GSSG ratio in cariac blood stasis group and carica phlegm stagnation group reduces compared with other two groups ( P < 0.05 ), be inclined to oxidized direction excursion .

【目的】探讨冠心病心血瘀阻证与纤溶酶原激活物抑制剂-1（PAI-1）基因启动子区4G/5G多态性的关系。

[ Objective ] To explore the relationship between 4G / 5G genetic polymorphism in the promoter of plasminogen activator inhibitor - 1 ( PAI - 1 ) and coronary heart disease with blood - stagnation syndrome .

结果CHD心血瘀阻证组在基因型M1M1和等位基因M1频率分布均显著高于健康对照组（P<0.05）；

Results The frequency distribution of the genotype of M1M1 and allele M1 of HBSS of CHD group was significantly higher than that in the healthy control group ( P < 0.05 ) .

结果：痰阻心脉、心血瘀阻、气阴两虚、气虚血瘀证型hs-CRP增高明显且与其它证型相比较有显著性差异（P<0.05）。

Results : The level of hs-CRP in the group of phlegm syndrome 、 blood stasis 、 deficiency of Qi and Yin and deficiency of Qi and Blood stasis syndrome was higher than those in other groups ( P < 0.05 ) .

且心血瘀阻、痰阻心脉证型血浆vWF、TXB2、6-keto-PGF1α水平均高于心肾阴虚、气阴两虚证型（P0.05，P0.01）。

The levels of plasma vWF , TXB2,6-Keto-PGF1 α of cardiac blood stasis group , phlegm retention in heart vessel group were significantly higher than those of deficiency of both heart-yin and kidney-yin group and asthenia of both qi and yin group ( P 0.05 ) .

冠心病心血瘀阻证和血瘀证差异的临床研究

Difference Between Blood-Stasis Syndrome and Coronary Heart Disease with Heart-Blood Stagnation Syndrome

基于气相色谱-质谱的大鼠心血瘀阻证血浆代谢组学研究

Research on Metabolomics of Heart Blood Stasis Rat Based on Gas Chromatography-Mass Spectrometry

结论：心达康胶囊治疗冠心病心绞痛（胸痹心血瘀阻证）安全、有效。

CONCLUSION : Xindakang capsule is an effective and safe drug in treating angina pectoris .

结论注射用红花黄色素治疗冠心病心绞痛心血瘀阻证疗效确切，同时安全性良好。

Conclusion SYI injection is effective and safe in treating CHD - AP with HBSS .

心血瘀阻证的计量诊断研究

Quantitative Diagnosis of heart blood stasis syndrome

心血瘀阻证遗传倾向的调查分析

A Survey on the Hereditary Tendency of the Pattern of Heart - Blood Stasis - Obstruction

心血瘀阻型；

Blood stasis resistance type ;

冠心病心血瘀阻证与血液纤溶酶原激活物抑制剂-1基因的关系

Relationship Between Plasminogen Activator Inhibitor - 1 Gene and Coronary Heart Disease with Blood - stagnation Syndrome

气虚、气滞在冠心病心血瘀阻证的发病作用研究

Influences of Qi Deficiency and Qi Stagnation in the Pathogenesis of Coronary Heart Disease with Heart-Blood Stagnation Syndrome

西红花多苷片治疗心血瘀阻型心绞痛30例疗效观察

Clinical effect of Saffron Multi-glycoside Tablet on 30 cases with cardiac angina belonging to heart blood stasis type

心血瘀阻型血浆纤维蛋白原水平与冠心病其他证型比较显著升高（P<0.05）；

The plasma Fg level of the coronary disease elevated significantly compared with other cards ( P < 0.05 );

血府逐瘀汤治疗冠心病心绞痛（心血瘀阻型）124例

Treating 124 Cases of Coronary Heart Disease and Angina ( Type of Cariac Blood Stasis ) with Xuefu Zhuyu Decoction

血府逐瘀汤在治疗冠心病心血瘀阻证的同时，亦明显改善心肌纤维化的程度。

XueFuZhuYu decoction can not only treat CHD with blood stasis syndrome , but also restrain and reverse myocardial fibrosis .

结论以冠脉结扎法建立的大鼠急性心肌缺血模型具有心血瘀阻的性质，今后的研究涉及胸痹心血瘀阻证型，似可采用冠脉结扎法造模。

Conclusion The model of acute myocardial ischemia induced by ligation of coronary artery shows the characters of heart-blood stasis .

结论：西红花多苷片对心血瘀阻型心绞痛有明显疗效。

Conclusion : There is notable effect to take Saffron Multi-glycoside Tablets for cardiac angina belonging to heart blood stasis type .

血府逐瘀汤干预冠心病心血瘀阻证心肌纤维化的临床研究

Clinical Research of Xuefu Zhuyu Decoction for the Intervention of Myocardial Fibrosis of Coronary Heart Disease Patients with Blood Stasis Syndrome

补肾活血法对冠心病稳定性心绞痛心血瘀阻证临床及脉搏波传导速度影响的研究

Bu Shen Huo Xue Fang 's Influence Research to the Stable Angina Pectoris Which to Heart-Blood-Stasis about the Clinical and Pulse Wave Velocity

结论：复方丹参制剂更适宜于符合心血瘀阻证的冠心病心电图缺血性ST&T改变患者。

Conclusions : Among the patients of CHD ischemia with ST-T changing on ECG , SMC is more effective to HBS syndrome type .